Estrogen On Human Umbilical Venous Endothelial Cells Apoptosis

PartⅠEstrogen on human umbilical venous endothelial cells apoptosisPurpose: Early postmenopausal(window) hormone replacement therapy, can reduce the occurrence of cardiovascular disease.Recent research suggests that endoplasmic reticulum stress response in hypertension plays an important role in the cardiovascular remodeling, and argued that the endoplasmic reticulum stress is the new treatment of cardiovascular disease targets. Our study investigated the impact of 17β-estradiol(E2) in reducing ERS in Human Umbilical Vein Endothelial Cells(HUVECs) exposed to tunicamycin(TM) and dithiothreitol(DTT).Methods: HUVECs were incubated for 10 hr in 10μmol/L TM or 8hr in 2mmol/L DTT with or without 10-8M E2 pretreatment.Another group of HUVECs were treated with ICI182,780 and G15 before adding E2. The expression of markers for ERS induced apoptosis(GRP78, cleaved caspase 12 and CHOP), were analyzed by western blot. Hochest staining was used to observe cell morphological changes.Results: In the presence of E2, expression of GRP78,cleaved caspase-12 and CHOP were significantly reduced. The protection effect of estrogen was ameliorated at the presence of ICI182,780 and G15. Morphological changes observed by the Hochest staining supported the results of western blot analysis.Conclusions: E2 can protect human endothelial cells from ERS induced apoptosis caused by TM and DTT,and by the addition of E2 E2 antagonist demonstrated the opposite effect.Mechanism for estrogen to maintain homeostasis by regulating ERS estrogen receptor, thereby protecting the cardiovascular provide new insights. Part II The study of perimenopausal symptoms in patients withpremature ovarian failure after myeloablative chemotherapy forHematologyObjective:To understand the occurrence of perimenopausal symptoms and self-awareness before and after hormone therapy in patients with premature ovarian failure after myeloablative chemotherapy for hematology.Methods:Premature ovarian failure patients(cases)after blood disease myeloablative chemotherapy, hematopoietic stem cell transplantation consulted to gynecological clinic of Peking University People’s Hospital from December 2011 to December 2013, meeting the diagnostic criteria. Investigated their menstruation, hormone levels, menopausal symptoms by Questionnaire and assessed perimenopause symptom relief features after hormone therapy.Results:1 there were 103 patients who completed the modified Kupperman score sheet in 142 cases, of which 82 people showed symptoms of menopause, accounting for 79.6% and Kupperman menopausal index score(KMI) averaged 13.50 points.96 people filled out the anxiety / depression(HAD) scale score,of which 6 people showed anxiety,an average of 8.83 points,while 4 people showed depression, with an average of 8.33 points.2 105 cases received hormone therapy( 94.6%),and 71 cases showed regularly withdrawal bleeding in following-up 95 cases.51 patients complained menstrual flow was significantly less than the amount of pre-transplant period,and blood darkened, which was statistically significant.3 The score of KMI averaged 6.7 after cyclical hormone replacement therapy, with a statistically significant decrease.Conclusions:1 Blood diseases myeloablative chemotherapy doses can lead to early failure of ovarian function.2 Hormone replacement therapy can relieve menopausal symptoms after myeloablative chemotherapy.3 Patients with ovarian premature aging of perimenopausal symptoms of cognitive deficiencies.